

Mari I. Suominen¹, Jenni Mäki-Jouppila¹, Jenni Bernoulli¹, Johanna Tuomela², Jussi M. Halleen¹, Sanna Timonen³, Elina Huovari³, Katja Suomi³, Swapnil Potdar³, Maria Nurmi³, Päivi Östling³, Jani Saarela³, Katja M. Fagerlund¹.

¹Pharmatest Services Ltd., Turku, Finland; ²University of Turku, Turku, Finland; ³Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland – E-mail correspondence to mari.suominen@pharmatest.com



Introduction


Prostate cancer (PC) is the most common malignancy in men and the second leading cause of cancer-related deaths. The majority of the PCs are classified as adenocarcinomas characterized by the expression of androgen receptor (AR) and prostate-specific antigen (PSA). Two of the most commonly used cell lines are LNCaP and PC-3 cells, derived from lymph node and bone metastases, respectively. In addition to these, VCaP cells, derived from vertebral metastases, are widely used in prostate cancer research. It has been well established that LNCaP and VCaP cells represent the conventional indolent form of PC expressing AR and PSA and are androgen-dependent. PC-3 cells, on the other hand, do not express AR and PSA, are androgen-independent, and represent the highly aggressive form.

Aim of the Study

Our goal was to compare the response of LNCaP, VCaP and PC-3 cells to a large panel of known anti-cancer compounds and determine the differences and similarities in sensitivity between these cell lines.

Materials and Methods

The drug sensitivity of the cell lines was assessed by applying a large panel of drugs covering both cancer chemo-therapeutics and many clinically available and emerging molecularly targeted drugs including conventional chemotherapy, kinase inhibitors, metabolic modifiers, rapalogs, differentiating/epigenetic modifiers, kinesin inhibitors, apoptotic modulators, NSAIDs, hormone therapy, immunomodulators and HSP inhibitors. A panel of about 460 compounds was tested in five concentrations covering a 10,000-fold drug-relevant concentration range in 384-well format. Cells were seeded to pre-drugged plates, followed by cell viability measurements (CellTiter-Glo) after 72 hours. Maximal and minimal responses to drugs were analyzed, the EC50 values were calculated and Drug Sensitivity Score (DSS) was calculated for each drug as a measure of reduced viability (1-3). A selective Drug Sensitivity Score (sDSS) was calculated to identify the selective drug response pattern of a cancer cell line (1-3).



Results / Drug sensitivity score (DSS)




Figure 1: Drug sensitivity score (DSS) of LNCaP, VCaP and PC-3 cells. DSS profile of LNCaP (A), VCaP (B), and PC-3 (C). 20 highest DSS values of LNCaP (D) VCaP (E) and PC-3 (F).

Results / Selective drug sensitivity score (sDSS)




Figure 2: Selective drug sensitivity score (sDSS) of LNCaP, VCaP and PC-3 cells. sDSS profile of LNCaP (A), VCaP (B), and PC-3 (C). 20 highest sDSS values of LNCaP (D, 196 compounds gave positive values), VCaP (E, 156 compounds gave positive values) and PC-3 (F, 67 compounds gave positive values) indicate compounds that are more active when compared to a reference panel consisting of LNCaP, VCaP and PC-3 cells.

Summary

As expected, the results indicate that LNCaP and VCaP cells in general were more sensitive to drugs of different categories than PC-3 cells. According to DSS analysis, all three cell lines showed sensitivity to conventional chemotherapy and kinase inhibitors. However, PC-3 cells were more sensitive to kinase inhibitors than conventional chemotherapy. Determining sDSS revealed specific sensitivities of each cell line:

- LNCaP cells were sensitive to conventional chemotherapy, such as anti-mitotic compounds, and kinase inhibitors, such as mTOR and AKT inhibitors.
- VCaP cells showed sensitivity to kinase inhibitors (such as Aurora kinase and IGF1R inhibitors) and HDAC inhibitors.
- PC-3 cells were sensitive to kinase inhibitors (such as CDK inhibitors).

Conclusions

We conclude that the cell-based compound screening combined with DSS analysis provides a possibility to profile cellular responses to an extensive collection of anti-cancer compounds. sDSS value can be used to identify the selective drug response pattern of different cancer cell lines. This enables identification of new indications for already existing drugs, finding vulnerabilities in different types of cancer cells and functional investigation of cellular pathways behind drug sensitivity or resistance.

References

1. Pemovska et al. 2013. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. *Cancer Discovery* 3(12):1416-29.
2. Yadav et al. 2014. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. *Scientific Reports* 4, 5193.
3. Pemovska et al. 2015. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. *Nature* 519, 102–105.